Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.54 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.50 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.50 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.47 |
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202439 | 0.98 | CA2 (0.56) | CA2CAMK2AALDH1A1TSHRAKR1B1 | |
| Felbinac SCHEMBL8346847 | 0.87 | HTT (0.72) | ALDH1A1TSHRAKR1B1NR1H4HPGD | |
| SCHEMBL11031787 | 0.87 | NR1H4 (0.49) | CA2CAMK2AALDH1A1TSHRAKR1B1 | |
| SCHEMBL28288707 | 0.84 | KMT2A (0.51) | CA2CAMK2AALDH1A1NR1H4HDAC1 | |
| SCHEMBL28287532 | 0.84 | RXRA (0.54) | CYP3A4NR1H4RXRARXRB | |
| SCHEMBL10611271 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL25180348 | 0.82 | CA2 (0.75) | CA2CAMK2AALDH1A1TSHRAKR1B1 | |
| Hydrochloric Acid SCHEMBL6765874 | 0.82 | CA2 (0.75) | CA2CAMK2AALDH1A1TSHRAKR1B1 | |
| SCHEMBL472272 | 0.82 | F2 (0.52) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2862421 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459585-B2 | Benzene derivatives and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20050165114-A1 | Benzene derivatives and pharmaceutical use thereof | AJINOMOTO CO. INC (JP) | 2005-07-28 | — | — | US | disclosed |
| US-6703379-B2 | ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT, ANTICANCER AGENTS, ANTIARTHRITIC AGENTS | AJINOMOTO CO., INC. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030166693-A1 | Benzene derivatives and pharmaceutical use thereof | AJINOMOTO CO., INC (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20010018441-A1 | Benzene derivatives and Pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2001-08-30 | — | — | US | disclosed |
| EP-1113000-A1 | BENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Ajinomoto Co., Inc. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-0279125-B1 | TETRAHYDROPYRIDO(1,2-A)INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-4968699-A | CENTRAL NERVOUS SYSTEM; ANTIISCHEMIC AND ANTIHYPOXIC AGENTS; ACTIVE AGAINST CEREBRAL OXYGEN DEFICIENCY | BEECHAM-WUELFING GMBH & CO. (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0279125-A1 | Tetrahydropyrido(1,2-a)indole derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166693-A1 | Benzene derivatives and pharmaceutical use thereof | NFKBIA, VCAM1, NFKB1 | CA2 1092/4885GAA 2081/4885HDAC1 154/4885 |
| US-20050165114-A1 | Benzene derivatives and pharmaceutical use thereof | NFKBIA, VCAM1, NFKB1 | CA2 1053/4885GAA 1930/4885HDAC1 186/4885 |
| US-20010018441-A1 | Benzene derivatives and Pharmaceutical use thereof | NFKBIA, VCAM1, NFKB1 | CA2 1092/4885GAA 2081/4885HDAC1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.